There is a significant gap in the knowledge and practice of integrating novel systemic therapies with radiotherapy in breast cancer management, particularly due to limited clinical trial data on their combined use.

Symptoms from cancer are often best palliated by multimodal therapies performed by different physicians.

With technological advances re-irradiation has rapidly become common and an important part of cancer management to new or recurrent tumors, yet is clinically challenging given risks of serious toxicity from cumulative doses.

Radiopharmaceutical Therapy (RPT) is an emerging modality with significant potential to impact future oncological management across many disease settings.

Theranostics, a treatment paradigm pairing diagnostic molecular imaging with radiopharmaceutical therapy (RPT), is resurgent, mainly driven by the FDA approvals of 177Lu-dotatate for neuroendocrine tumors and 177Lu-PSMA-617 for prostate cancer.

Radiation dosimetry plays a critical role in the development and application of radiotherapeutic pharmaceuticals, ensuring both efficacy and safety in treatment.

Radiopharmaceuticals are an increasingly utilized therapeutic option for the treatment of malignancies.

Exercise has been shown to improve numerous physical, psychosocial and clinical outcomes in those diagnosed with cancer.

Patient reported outcomes (PROs) are a key component of evaluating cancer therapy. For clinical trialists, the proper design, implementation and evaluation of patient reported outcomes is critical for designing studies that will impact and inform daily practice.